CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 160 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,128,000 | +39.8% | 150,000 | +72.4% | 1.16% | +12.6% |
| Q2 2023 | $2,952,962 | +64.1% | 87,031 | +74.1% | 1.03% | +73.6% |
| Q1 2023 | $1,799,000 | -63.3% | 50,000 | -54.5% | 0.59% | -69.1% |
| Q4 2022 | $4,902,700 | +118.0% | 110,000 | +37.5% | 1.92% | +206.2% |
| Q3 2022 | $2,249,000 | -54.9% | 80,000 | -56.8% | 0.63% | -70.1% |
| Q2 2022 | $4,987,000 | +17.1% | 185,000 | +48.0% | 2.10% | +208.7% |
| Q1 2022 | $4,258,000 | +10.2% | 125,000 | +25.0% | 0.68% | -51.5% |
| Q4 2021 | $3,864,000 | +78.2% | 100,000 | +149.0% | 1.40% | +156.0% |
| Q3 2021 | $2,168,000 | +29.7% | 40,154 | -19.7% | 0.55% | -8.5% |
| Q2 2021 | $1,672,000 | -37.6% | 50,000 | -61.5% | 0.60% | -34.1% |
| Q1 2021 | $2,678,000 | +103.8% | 130,000 | +73.3% | 0.91% | +30.6% |
| Q4 2020 | $1,314,000 | – | 75,000 | – | 0.70% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |